Compare Amgen, Inc. (AMGN) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Credo Technology Group Holding Ltd — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Credo Technology Group Holding Ltd trades at $251.35 (market cap $48.07B). The key difference: Amgen, Inc. is far larger — about 4.1× Credo Technology Group Holding Ltd's market cap, and Amgen, Inc. pays a 2.77% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| AMGN | CRDO | |
|---|---|---|
Market Cap | $196.12B | $48.07B |
Sector | Health | Technology |
52-Week High | $388.16 | $302.52 |
52-Week Low | $271.18 | $87.81 |
Enterprise Value | $241.41B | $46.65B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CRDO trades at $257.79, down 2.96% today but maintains strong bullish momentum with analyst consensus at 'Buy' (86.7% of 15 analysts). The stock shows robust fundamentals with 35.37% net income margin and triple-digit revenue growth projections for 2026. Recent earnings consistently beat expectations, and technical indicators suggest bullish momentum with support at $258 and resistance at $276.
Outlook remains positive given AI infrastructure demand and strong financial performance, though elevated valuations (P/E 102.7) and customer concentration risks warrant caution. The consensus price target of $273.33 implies 6% upside potential from current levels, supported by institutional optimism and expanding market opportunities in high-speed connectivity solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
